Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Imatinib was first approved for the treatment of Philadelphi
2024-12-30
Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h
-
br Conclusions Triptans are HT B
2024-12-30
Conclusions Triptans are 5-HT1B/1D/(1F) receptors agonists and are considered as the gold standard for acute migraine treatment that have been proven effective. Unfortunately, they are contraindicated in patients with cardiovascular diseases due to their vasoconstrictor (side) effects (MaassenVan
-
Netilmicin Sulfate The reduced IFN production seen with BPAL
2024-12-30
The reduced IFNγ production seen with BPAL10-primed splenocytes could potentially be attributed to the impaired intracellular survival of B. pertussis, thereby leading to a weakened induction of cell-mediated immunity. Earlier studies have suggested an antimicrobial role of IFNγ in mediating the eli
-
Patients with ADA SCID may experience autoimmune AEs
2024-12-30
Patients with ADA-SCID may experience autoimmune AEs after SCT (and/or during ERT) that are thought to be related to immune dysregulation prior to achieving complete immune reconstitution. The more common autoimmune manifestations include hemolytic anemia, hypothyroidism, and immune thrombocytopenia
-
In the olfactory bulb expression was
2024-12-30
In the olfactory bulb, expression was especially prominent in the mitral cell layer from embryonic stages to adult tissues (Figs. 1D–G). By E14–E16, Ack1 signal was remarkably intense in the proliferative ventricular zone (Fig. 1D). From E18 to adult, expression was also observed in glomerular and g
-
br Introduction Myasthenia gravis MG is an autoimmune
2024-12-30
Introduction Myasthenia gravis (MG) is an autoimmune disease in which antibodies against targets on the postsynaptic muscle membrane cause neuromuscular transmission failure. About 85% of patients with MG have autoantibodies against Gemfibrozil mg receptor (AChR) [1]. In AChR negative MG patient
-
REM sleep is proposed to create an environment to facilitate
2024-12-30
REM sleep is proposed to create an environment to facilitate plasticity processes that create a generalized downregulation of synaptic strength (Grosmark et al., 2012; Tononi and Cirelli, 2014), while synapses are upregulated specifically by the reactivation of neuronal firing sequences experienced
-
After infection with Salmonella those bacteria that are
2024-12-27
After infection with Salmonella those bacteria that are not targeted by autophagy of the complete Salmonella-containing phagosome (see above) but are living freely in the cytosol can be eliminated by xenophagy, that is direct targeting of the ‘naked’ bacteria to the autophagic pathway. The type III
-
Phosphoinositide kinase PI K Akt has been well demonstrated
2024-12-27
Phosphoinositide 3-kinase (PI3K)/Akt has been well demonstrated in the protection of myocardial cell against IR injury via increasing cardiomyocyte survival, inhibiting excessive autophagy, et al. (Kong et al., 2016). The Baricitinib phosphate australia of ERK1/2 also involves in the regulation of
-
l Arginine supplementation was reported to be
2024-12-27
l-Arginine supplementation was reported to be efficient, inefficient or toxic in aged patients. The present study does not support our hypothesis that increased tissue arginase activity may account for the ineffectiveness and even the toxicity of l-arginine supplementation in ageing. Indeed, except
-
br Conflicts of interest br Acknowledgements This work was s
2024-12-27
Conflicts of interest Acknowledgements This work was sponsored by grants from Longyan University Scientific Research Fund for the Young Scholars (LQ2016010), Middle-aged and Young Teachers Education Research Projects of Fujian Province (JAT170569), Longyan University Scientific Research Fund f
-
Analyses of brain CSCs isolated from pediatric
2024-12-27
Analyses of Dopamine receptor agonist CSCs isolated from 24 pediatric and six adult brain tumors detected ALDH levels proportional to tumor type and aggressiveness. ALDH-expressing cells (ALDH+) formed spheroids while ALDH1 pharmacological inhibition by a combination of DEAB and RA decreased signifi
-
Studies on both TCDD treated mice and AhR
2024-12-27
Studies on both TCDD treated mice and AhR null mice have also pointed to a role of AhR in hematopoiesis [65], [66]. Singh et al. showed that AhR is a negative regulator of HSC (hematopoietic stem cell) proliferation, while deletion of AhR leads to spleen enlargement in juvenile and adult mice [67].
-
We stimulated HNEpC cells with LPS
2024-12-27
We stimulated HNEpC cells with LPS found that the secretion of inflammatory cytokines and the expression of AHR was increased significantly, and miR124 was reduced. It has been found that LPS as a foreign substance can bind to the TLR family of proteins to activate intracellular AHR signaling [[19],
-
hydroxydopamine OHDA is a selective catecholaminergic neurot
2024-12-26
6-hydroxydopamine (6-OHDA) is a selective catecholaminergic neurotoxin mainly used to generate lesions in the nigrostriatal pathway in rats (Ungerstedt, 1968). The most common use of 6-OHDA is via unilateral injection into the rat medial forebrain bundle (MFB). DA depletion, nigral DA cell loss, and